$BOMO
bowmo, Inc.

2023 Q2 Form 10-Q Financial Statement

#000157587223000884 Filed on June 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $4.476K $0.00
YoY Change
Cost Of Revenue $0.00 $27.58K
YoY Change -100.0%
Gross Profit $4.476K $61.09K
YoY Change -92.67%
Gross Profit Margin 100.0%
Selling, General & Admin $165.1K $388.0K $121.1K
YoY Change -47.93% 220.25% 12.08%
% of Gross Profit 8667.34% 198.3%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $165.1K $387.9K $121.1K
YoY Change -47.93% 220.25% 12.08%
Operating Profit -$165.1K -$383.5K -$60.05K
YoY Change -40.35% 538.59%
Interest Expense $227.9K $269.5K -$94.31K
YoY Change 497.39% -385.76% -88.52%
% of Operating Profit
Other Income/Expense, Net -$1.101M $1.001M -$6.555K
YoY Change 10592.33% -15372.54%
Pretax Income -$1.266M $617.6K -$215.4K
YoY Change 341.03% -386.69% -81.98%
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings -$1.266M $617.6K -$215.4K
YoY Change 341.03% -386.69% -81.98%
Net Earnings / Revenue 13798.97%
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 -$26.34
COMMON SHARES
Basic Shares Outstanding 31.30B 31.30B 18.15M
Diluted Shares Outstanding 32.27B shares 28.16B 18.15M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $77.75K $87.62K $2.750K
YoY Change -72.7% 3086.18%
Cash & Equivalents $77.75K $87.62K $2.750K
Short-Term Investments
Other Short-Term Assets $860.00 $860.00
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $78.60K $88.47K $2.750K
YoY Change -72.4% 3117.24%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $78.60K $88.47K $2.750K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $78.60K $88.47K $2.750K
YoY Change -72.4% 3117.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $952.9K $952.9K $326.4K
YoY Change 142.92% 191.93% 0.0%
Accrued Expenses $329.3K $332.0K $1.632M
YoY Change -72.18% -79.65% 13.91%
Deferred Revenue
YoY Change
Short-Term Debt $775.1K $607.2K $847.1K
YoY Change 170.83% -28.32% -48.45%
Long-Term Debt Due $563.0K $303.5K
YoY Change 118.91%
Total Short-Term Liabilities $6.017M $4.645M $3.014M
YoY Change 79.7% 54.1% -46.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $260.5K $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $260.5K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.017M $4.645M $3.014M
Total Long-Term Liabilities $0.00 $260.5K $0.00
Total Liabilities $6.017M $4.906M $3.014M
YoY Change 64.61% 62.74% -46.63%
SHAREHOLDERS EQUITY
Retained Earnings -$9.892M -$8.626M
YoY Change 97.27%
Common Stock $324.4K $313.0K
YoY Change 107.57%
Preferred Stock
YoY Change
Treasury Stock (at cost) $773.5K $773.5K
YoY Change 0.0%
Treasury Stock Shares $2.917K
Shareholders Equity -$5.938M -$4.817M -$906.4K
YoY Change
Total Liabilities & Shareholders Equity $78.60K $88.47K $2.750K
YoY Change -72.4% 3117.24%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.266M $617.6K -$215.4K
YoY Change 341.03% -386.69% -81.98%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$8.890K -$79.49K -$2.960K
YoY Change -93.28% 2585.37%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -980.0 0.000
YoY Change -100.23%
NET CHANGE
Cash From Operating Activities -8.890K -79.49K -2.960K
Cash From Investing Activities 0.000
Cash From Financing Activities -980.0 0.000
Net Change In Cash -9.870K -79.49K $0.00
YoY Change -103.43%
FREE CASH FLOW
Cash From Operating Activities -$8.890K -$79.49K -$2.960K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock
CY2023Q1 dei Trading Symbol
TradingSymbol
BOMO
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31297119462
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87616
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
167103
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15542
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
858
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
858
CY2023Q1 us-gaap Assets Current
AssetsCurrent
88474
CY2022Q4 us-gaap Assets Current
AssetsCurrent
183503
CY2023Q1 us-gaap Assets
Assets
88474
CY2022Q4 us-gaap Assets
Assets
183503
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
952859
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
813378
CY2023Q1 bomo Accrued Expenses Current
AccruedExpensesCurrent
200000
CY2022Q4 bomo Accrued Expenses Current
AccruedExpensesCurrent
200286
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
331986
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
366622
CY2023Q1 bomo Accrued Officer Compensation
AccruedOfficerCompensation
1113211
CY2022Q4 bomo Accrued Officer Compensation
AccruedOfficerCompensation
1074361
CY2023Q1 us-gaap Loans Payable Current
LoansPayableCurrent
113006
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
113006
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
190500
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
190500
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
607222
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
669581
CY2023Q1 bomo Preferred Stocks Redemption Premium
PreferredStocksRedemptionPremium
199684
CY2022Q4 bomo Preferred Stocks Redemption Premium
PreferredStocksRedemptionPremium
219687
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
936636
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2172250
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4645104
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5819671
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001381871
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
607222
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-54624
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Bowmo, inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4144571
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
99 Wall Street
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 891
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10005
CY2023Q1 dei City Area Code
CityAreaCode
212
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
398-0002
CY2023Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
260494
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
260494
CY2023Q1 us-gaap Liabilities
Liabilities
4905598
CY2022Q4 us-gaap Liabilities
Liabilities
6080165
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31297119462
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31297119462
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27049736362
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27049736362
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
312971
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
270497
CY2023Q1 bomo Common Stock Shares Yet To Be Issued
CommonStockSharesYetToBeIssued
2550000
CY2022 bomo Common Stock Shares Yet To Be Issued
CommonStockSharesYetToBeIssued
2550000
CY2023Q1 bomo Common Stock Value Yet To Be Issued
CommonStockValueYetToBeIssued
26
CY2022Q4 bomo Common Stock Value Yet To Be Issued
CommonStockValueYetToBeIssued
26
CY2023Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
2917
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
2917
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
773500
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
773500
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4018454
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3599032
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8626283
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9243925
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4817124
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5896662
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
88474
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
183503
CY2023Q1 us-gaap Revenues
Revenues
4476
CY2022Q1 us-gaap Revenues
Revenues
88667
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
0
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
27579
CY2023Q1 us-gaap Gross Profit
GrossProfit
4476
CY2022Q1 us-gaap Gross Profit
GrossProfit
61088
CY2023Q1 us-gaap Salaries And Wages
SalariesAndWages
121314
CY2022Q1 us-gaap Salaries And Wages
SalariesAndWages
102268
CY2023Q1 bomo Consulting Expense
ConsultingExpense
30000
CY2022Q1 bomo Consulting Expense
ConsultingExpense
0
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
160054
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
10000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
76581
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6327
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
387949
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
118595
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-383473
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-57507
CY2023Q1 us-gaap Interest Expense
InterestExpense
269500
CY2022Q1 us-gaap Interest Expense
InterestExpense
5010
CY2023Q1 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
0
CY2022Q1 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
0
CY2023Q1 bomo Grant Income
GrantIncome
0
CY2022Q1 bomo Grant Income
GrantIncome
0
CY2023Q1 us-gaap Gain Loss On Condemnation
GainLossOnCondemnation
0
CY2022Q1 us-gaap Gain Loss On Condemnation
GainLossOnCondemnation
0
CY2023Q1 bomo Initial Recognition Of Derivative Liability
InitialRecognitionOfDerivativeLiability
32429
CY2022Q1 bomo Initial Recognition Of Derivative Liability
InitialRecognitionOfDerivativeLiability
0
CY2023Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
1303044
CY2022Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-1545
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1001115
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6555
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
617642
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-64062
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
617642
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-64062
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28158862202
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28158862202
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18150000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18150000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5896662
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28314
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
14995
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
418587
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
617642
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4817124
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5374395
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-64062
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-5438.457
CY2023Q1 us-gaap Profit Loss
ProfitLoss
617642
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-64062
CY2023Q1 bomo Reconciliation Of Debt Balances
ReconciliationOfDebtBalances
30000
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
245146
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
96314
CY2023Q1 us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
17075
CY2023Q1 bomo Initial Derivative Expense
InitialDerivativeExpense
32429
CY2023Q1 bomo Derivative Gain Loss On Derivative Fair Value
DerivativeGainLossOnDerivativeFairValue
-1303044
CY2022Q1 bomo Derivative Gain Loss On Derivative Fair Value
DerivativeGainLossOnDerivativeFairValue
1545
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-15542
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2112
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
138972
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-286
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5011
CY2023Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-8127
CY2023Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
38850
CY2022Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
48268
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3108
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-79487
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14458
CY2022Q1 bomo Proceeds From Loans Payable
ProceedsFromLoansPayable
269100
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
269100
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-79487
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
254642
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167103
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
385
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87616
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
255027
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
940681
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1197681
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
333460
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
528100
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates</div></div></div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; background: none;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Concentrations of Credit Risk</div></div></div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; white-space: pre-wrap; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"> </div></div> <div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We maintain our cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. We continually monitor our banking relationships and consequently have not experienced any losses in our accounts. We believe we are not exposed to any significant credit risk on cash.</div></div>
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
669581
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4476
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
88667
CY2023Q1 us-gaap Premiums Earned Net
PremiumsEarnedNet
1265684
CY2023Q1 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
199684
CY2021Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
110992
CY2022 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
2718645
CY2022 bomo Derivative Liability Transfer To Put Premium
DerivativeLiabilityTransferToPutPremium
-112537
CY2023Q1 bomo Going Concern
GoingConcern
<div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; background: none;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2 – GOING CONCERN</div></div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; background: none;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="margin: 0px 0px 0px 0in; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; line-height: 12pt; background: none;;text-indent: 0px;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; line-height: 12pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going-concern basis. The going concern basis assumes that assets are realized, and liabilities are extinguished in the ordinary course of business at amounts disclosed in the consolidated financial statements. The Company has incurred recurring losses from operations. The Company has an accumulated deficit of approximately $8.6 million.  The  company historically has had negative cash flow from operations. The Company’s ability to continue as a going concern depends upon its ability to obtain adequate funding to support its operations through continuing investments of debt and/or equity by qualified investors/creditors, internally generated working capital and monetization of intellectual property assets. These factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management is currently pursuing a business strategy which includes raising the necessary funds to finance the Company’s development and marketing efforts.</div></div>
CY2023Q1 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
8600000
CY2022Q1 us-gaap Business Combination Separately Recognized Transactions Revenues And Gains Recognized
BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized
14692
CY2022Q1 us-gaap Business Combination Separately Recognized Transactions Net Gains And Losses
BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses
21862
CY2023Q1 us-gaap Other Loans Payable
OtherLoansPayable
564000
CY2022Q4 us-gaap Other Loans Payable
OtherLoansPayable
564000
CY2022 bomo Derivative Gain Loss On Derivative Fair Value
DerivativeGainLossOnDerivativeFairValue
-544850
CY2022Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
2172250
CY2023Q1 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
67429
CY2023Q1 bomo Derivative Gain Loss On Derivative Fair Value
DerivativeGainLossOnDerivativeFairValue
-1303044
CY2023Q1 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
936636
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31297119462
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27049736362
CY2023Q1 bomo Extinguishment Of Convertible Debt
ExtinguishmentOfConvertibleDebt
4247383100
CY2023Q1 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
4247383100
CY2023Q1 bomo Debt Instrument Face Value
DebtInstrumentFaceValue
325000
CY2023Q1 us-gaap Debt Instrument Increase Decrease Other Net
DebtInstrumentIncreaseDecreaseOtherNet
26509
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
17075
CY2023Q1 bomo Total Debt Current
TotalDebtCurrent
368584
CY2022Q4 bomo Share Available To Purchase With Stock Warrants Outstanding Number
ShareAvailableToPurchaseWithStockWarrantsOutstandingNumber
5616000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.0001
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
6.09
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
200000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.0001
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2023Q1 bomo Weighted Average Price Forfeited
WeightedAveragePriceForfeited
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2023Q1 bomo Weighted Average Fair Value Expired
WeightedAverageFairValueExpired
0
CY2023Q1 bomo Share Available To Purchase With Stock Warrants Outstanding Number
ShareAvailableToPurchaseWithStockWarrantsOutstandingNumber
5816000000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.0001
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.86
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
5816000000
CY2023Q1 bomo Weighted Average Price Exercisable
WeightedAveragePriceExercisable
0.0001
CY2023Q1 bomo Weighted Average Fair Value Exercisable Outstanding
WeightedAverageFairValueExercisableOutstanding
5.86
CY2023Q1 bomo Number Outstanding In Shares
NumberOutstandingInShares
5816000000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P5Y10M9D
CY2023Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.0001
CY2022 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
40875
CY2021 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
50500
CY2019Q3 bomo Salary Per Month
SalaryPerMonth
10000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
562000
CY2023Q1 bomo Amount Of Indebtedness
AmountOfIndebtedness
1200000
CY2017Q1 bomo Obtained Default Judgment
ObtainedDefaultJudgment
27084

Files In Submission

Name View Source Status
0001575872-23-000884-index-headers.html Edgar Link pending
0001575872-23-000884-index.html Edgar Link pending
0001575872-23-000884.txt Edgar Link pending
0001575872-23-000884-xbrl.zip Edgar Link pending
bomo-20230331.htm Edgar Link pending
bomo-20230331.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nm037_001.jpg Edgar Link pending
nm037_002.jpg Edgar Link pending
nm037_ex31.htm Edgar Link pending
nm037_ex32.htm Edgar Link pending
bomo-20230331_cal.xml Edgar Link unprocessable
bomo-20230331_lab.xml Edgar Link unprocessable
bomo-20230331_pre.xml Edgar Link unprocessable
bomo-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bomo-20230331_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending